Gastroenterology

Read about how mirikizumab shows strong results for IBD, improving remission and response rates.

Results from the phase 3 QUASAR trials show that guselkumab offers effective and safe induction and maintenance therapy for moderate-to-severe ulcerative colitis, with nearly 50% of patients achieving clinical remission after one year.

Pregnant individuals with IBD prescribed low-dose aspirin were no more likely to experience flares than those not on aspirin, according to a new study, easing concerns about its use in this high-risk population.

A new analysis from nearly 20,000 participants in the U.S. NHANES study has identified the platelet-to-high-density lipoprotein ratio (PHR) as a strong predictor of gastrointestinal cancer risk.

Tirzepatide linked to more GI issues than semaglutide in new study on weight-loss drugs without diabetes. Read more!

While both bariatric surgeries aid weight loss and quality of life, Roux-en-Y gastric bypass shows greater benefits for reducing acid reflux and oesophageal inflammation.

Research shows that compounds produced during cabbage fermentation protect gut lining from cytokine damage, highlighting the potential of fermented foods in gut health.

A new umbrella meta-analysis finds strong evidence that probiotics, particularly multi-strain formulations, reduce the risk of necrotising enterocolitis (NEC) and death in preterm babies.